Back to search results

A Study of ALN-BCAT for Advanced Liver Cancer

This study is testing a new treatment called ALN-BCAT, both on its own and in combination with pembrolizumab, for people with advanced or metastatic hepatocellular carcinoma (HCC), a type of liver cancer. You might be able to join if you have HCC that has been confirmed, have already received at least one other treatment for your cancer, and have a specific genetic change called a WNT-pathway activating mutation. The main goals are to understand the safety and side effects of ALN-BCAT and to find the best dose. Later, the study will also look at how well the treatment works against the cancer. The study plans to enroll 158 participants, but its current status is unclear.

Study design
This is an interventional study planning to enroll 158 participants. It will test ALN-BCAT alone and with pembrolizumab.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Safety will be monitored from the first dose until 30-37 days after the last dose of study drug.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06600321

A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma

Recruiting
PHASE1Ages 18+InterventionalTreatment
Alnylam Pharmaceuticals
~158 participants
Updated 2026-06-17 on ClinicalTrials.gov
What's tested:ALN-BCATPembrolizumab

At a glance

Recruiting sites
22 of 23 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Frequency of Adverse Events (AEs)
Measured over From the time of first dose of study drug administration to 30-37 days after the last dose
+3 more outcomes measured

Conditions

Advanced Hepatocellular Carcinoma
Metastatic Hepatocellular Carcinoma

Explore related trials

Hepatocellular CarcinomaCTNNB1 Gene

NCT06600321

Where you'd take part

This study runs at 23 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Clinical Trial Site

    Phoenix, Arizonano site contact published

    Recruiting

  • Clinical Trial Site

    La Jolla, Californiano site contact published

    Recruiting

  • Clinical Trial Site

    Los Angeles, Californiano site contact published

    Recruiting

  • Clinical Trial Site

    Jacksonville, Floridano site contact published

    Recruiting

  • Clinical Trial Site

    Atlanta, Georgiano site contact published

    Recruiting

  • Clinical Trial Site

    Chicago, Illinoisno site contact published

    Recruiting

  • Clinical Trial Site

    Ann Arbor, Michiganno site contact published

    Recruiting

  • Clinical Trial Site

    Rochester, Minnesotano site contact published

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Medical Director · STUDY_DIRECTOR · Alnylam Pharmaceuticals

Who to contact

Alnylam Clinical Trial Information Line
[email protected]
1-877-ALNYLAM
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Has HCC confirmed histologically or cytologically, or, for patients with liver cirrhosis, clinically by the American Association for the Study of Liver Diseases (AASLD) criteria
Has had at least one line of systemic therapy for unresectable advanced or metastatic disease
Has at least one wingless-related integration site (WNT)-pathway activating mutation
Child-Pugh class A or B7

Exclusion

Has fibrolamellar HCC, sarcomatoid HCC, or mixed cholangio-HCC tumors
Has symptomatic extrahepatic disease
Has received anti-cancer therapy or investigational drugs ≤3 weeks prior to the first dose of study drug

What this trial measures

  • Frequency of Adverse Events (AEs)From the time of first dose of study drug administration to 30-37 days after the last dose
  • Severity of AEsFrom the time of first dose of study drug administration to 30-37 days after the last dose
  • Dose Escalation: Occurrence of Dose-limiting Toxicities (DLTs)From the time of first dose of study drug administration up to 21 days
  • Dose Expansion: Antitumor Activity as assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)Up to 30-37 Days after the last dose